Photodynamic Therapy for Cholangiocarcinoma

The prognosis of perihilar cholangiocarcinoma (CC) is limited by tumor spread along the biliary tree leading to refractory obstructive cholestasis, cholangitis, and liver failure. Palliation with biliary endoprostheses yields median survival times between 4 and 6 months for nonresectable CC. Tumor ablation with photodynamic therapy (PDT) combined with biliary stenting reduces cholestasis and significantly improves median survival time to 11.5 to 16.2 months. PDT with porfimer and laser light of 630 nm provides tumoricidal tissue penetration to a depth of only 4 to 4.5 mm that does not eradicate most tumors. Time to progression lasts approximately 6 months; in other words, PDT is required twice annually. PDT costs less and enhances quality of life and survival time as compared with chemotherapy for metastatic colon cancer. These data suggest that PDT should be offered as part of the palliative treatment of CC in hepatobiliary referral centers.

KEYWORDS

Bile duct cancer - cholangiocarcinoma - hematoporphyrin derivative - photodynamic therapy - photosensitizer - porfimer sodium

REFERENCES

• 1 de Groen P C, Gores G J, LaRusso N F et al.. Biliary tract cancers.  N Engl J Med. 1999;  341 1368-1378 , (Review)
• 2 Gores G J. Cholangiocarcinoma: current concepts and insights.  Hepatology. 2003;  37 961-969 , (Review)
• 3 Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features.  Am J Med. 1965;  38 241-256
• 4 Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma.  Ann Surg. 1992;  215 31-38
• 5 Henson D E, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade and survival rates.  Cancer. 1992;  70 1498-1501
• 6 Kimura W, Nagai H, Atomi Y et al.. Clinico-pathological characteristics of hepatic hilar bile duct carcinoma.  Hepatogastroenterology. 1993;  40 21-27
• 7 McCaughan J S, Mertens B F, Cho C, Barabash R D, Payton H W. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report.  Arch Surg. 1991;  126 111-113
• 8 Ortner M A, Liebetruth J, Schreiber S et al.. Photodynamic therapy of nonresectable cholangiocarcinoma.  Gastroenterology. 1998;  114 536-542
• 9 Berr F, Tannapfel A, Lamesch P et al.. Neoadjuvant therapy before curative resection of proximal bile duct carcinoma (case report).  J Hepatol. 2000;  32 352-357
• 10 Berr F, Wiedmann M, Tannapfel A et al.. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.  Hepatology. 2000;  31 291-298
• 11 Rumalla A, Baron T, Wang K et al.. Endoscopic application of photodynamic therapy for cholangiocarcinoma.  Gastrointest Endosc. 2001;  53 500-504
• 12 Zoepf T, Jakobs R, Arnold J C et al.. Photodynamic therapy for palliation of nonresectable bile duct cancer-preliminary results with a new diode laser system.  Am J Gastroenterol. 2001;  96 2093-2097
• 13 Dumoulin F L, Gerhardt T, Fuchs S et al.. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma.  Gastrointest Endosc. 2003;  57 860-867
• 14 Ortner M E, Caca K, Berr F et al.. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.  Gastroenterology. 2003;  125 1355-1363
• 15 Wiedmann M, Caca K, Berr F et al.. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma.  Cancer. 2003;  97 2783-2790
• 16 Davids P HP, Groen A K, Rauws E AJ et al.. Randomised trial of self-expanding metal stents versus polyethylene stents for malignant distal biliary obstruction.  Lancet. 1992;  340 1488-1492
• 17 Murad A M, Guimaraes R C, Aragao B C et al.. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.  Am J Clin Oncol. 2003;  26 151-155
• 18 Whittington R, Neuberg D, Tesfer W J et al.. Protracted intravenous fluorouracil infusion with radiation therapy in th management of localized pancreatobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.  J Clin Oncol. 1995;  13 227-232
• 19 Burke E C, Jarnagin E R, Hochwald S N et al.. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system.  Ann Surg. 1998;  228 385-394
• 20 Neuhaus P, Jonas S, Bechstein W O et al.. Extended resections for hilar cholangiocarcinoma.  Ann Surg. 1999;  230 808-819
• 21 Pichlmayr R, Weimann A, Klempnauer J et al.. Surgical treatment in proximal bile duct cancer. A single-center experience.  Ann Surg. 1996;  224 628-638 , (Review)
• 22 Madriaga J R, Iwatsuki S, Todo S et al.. Liver resection for hilar and peripheral cholangiocarcinoma: a study of 62 cases.  Ann Surg. 1998;  227 70-90
• 23 Launois B, Terblanche J, Lakehal M et al.. Proximal bile duct cancer: high resectability rate and 5-year survival.  Ann Surg. 1999;  230 266-275
• 24 Kosuge T, Yamamoto J, Shimada K et al.. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection.  Ann Surg. 1999;  230 663-671
• 25 Jarnagin W R, Fong Y, DeMatteo R P et al.. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.  Ann Surg. 2001;  234 507-517
• 26 Farley D R, Weaver A L, Nagorney D M. “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention.  Mayo Clin Proc. 1995;  70 425-429
• 27 Devière J, Baize M, de Toeuf J, Cremer M. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage.  Gastrointest Endosc. 1988;  34 95-101
• 28 Polydorou A A, Cairns S R, Dowsett J F et al.. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion.  Gut. 1991;  32 685-689
• 29 Ducreux M, Liguory C, Lefebvre J F et al.. Management of malignant hilar biliary obstruction by endoscopy. Results and prognostic factors.  Dig Dis Sci. 1992;  37 778-783
• 30 Liu C-L, Lo C-M, Lai E CS, Fan S-T. Endoscopic retrograde cholangiopancreato-graphy and endoscopic endoprosthesis insertion in patients with Klatskin tumors.  Arch Surg. 1998;  133 293-296
• 31 Chang W H, Kortan P, Haber G B. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage.  Gastrointest Endosc. 1998;  47 354-362
• 32 Molt P, Hopfan S, Watson R et al.. Intraluminal radiation therapy in the management of malignant biliary obstruction.  Cancer. 1986;  57 536-544
• 33 Kamada T, Saitou H, Takamura A, Nojima T, Okushiba S I. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy.  Int J Radiat Oncol Biol Physiol. 1996;  34 767-774
• 34 Bowling T E, Galbraith S M, Hatfield A RW et al.. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma.  Gut. 1996;  39 852-855
• 35 Ede R J, Williams S J, Hatfield A RW et al.. Endoscopic management of inoperable cholangiocarcinoma using iridium-192.  Br J Surg. 1989;  76 867-869
• 36 Tsujino K, Landry J C, Smith R G et al.. Definitive radiation therapy for extrahepatic bile duct carcinoma.  Radiology. 1995;  196 275-280
• 37 Kuvshinoff B W, Armstrong J G, Fong Y et al.. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy.  Br J Surg. 1995;  82 1522-1525
• 38 Eschelman D J, Shapiro M J, Bonn J et al.. Malignant biliary obstruction: Long-term experience with Gianturco stents and combined-modality radiation therapy.  Radiology. 1996;  200 717-724
• 39 Foo M L, Gunderson L L, Bender C E, Buskirk S J. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma.  Int J Radiat Oncol Biol Physiol. 1997;  39 929-935 , (Review)
• 40 Dougherty T J, Gomer C J, Henderson B W et al.. Photodynamic therapy (review).  J Natl Cancer Inst. 1998;  90 889-904
• 41 Hsi R A, Rosenthal D I, Glatstein E. Photodynamic therapy in the treatment of cancer: current state of the art.  Drugs. 1999;  57 725-734 , (Review)
• 42 Hayata Y, Kato H, Konaka C et al.. Hematoporphyrin derivative and photoradiation therapy in early-stage lung cancer.  Lasers Surg Med. 1984;  4 39-47
• 43 Prout G R, Lin C W, Benson R J et al.. Photodynamic therapy of superficial transitional cell carcinoma of the bladder.  N Engl J Med. 1987;  317 1251-1255
• 44 Edell E, Cortese D. Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection.  Chest. 1992;  102 1319-1322
• 45 Sibille A, Lambert R, Souquet J C, Sabben G, Descos F. Long-term survival after photodynamic therapy for esophageal cancer.  Gastroenterology. 1995;  108 337-344
• 46 Overholt B, Panjehpour M, Haydek J. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.  Gastrointest Endosc. 1999;  49 1-7
• 47 Wong Kee Song L M, Wang K K, Zinsmeister A R. Mono-L-aspartyl chlorine 6 and hematoporphyrin derivative in photodynamic therapy administered to a human cholangiocarcinoma model.  Cancer. 1998;  82 421-427
• 48 Oertel M, Schastak S I, Tannapfel A et al.. Novel bacteriochlorine for high tissue-penetration: photodynamic properties in human biliary tract cancer cells in vitro and in a mouse tumour model.  J Photochem Photobiol B. 2003;  71 1-10
• 49 Pahernik S A, Dellian M, Berr F et al.. Distribution and pharmacokinetics of Photofrin in human bile duct cancer.  J Photochem Photobiol B. 1998;  47 58-62
• 50 Zoepf T, Jakobs R, Rosenbaum A et al.. Photodynamic therapy with 5-amino-levulinic acid is not effective in bile duct cancer.  Gastrointest Endosc. 2001;  54 763-766
• 51 Schoefl R, Haefner M, Wrba F et al.. Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses.  Scand J Gastroent. 1997;  32 363-368
• 52 Kluge R, Schmidt F, Caca K et al.. Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.  Hepatology. 2001;  33 1029-1035
• 53 Lai E CS, Patterson I A, Tam P C et al.. Severe acute cholangitis: The role for emergency nasobiliary drainage.  World J Surg. 1990;  107 268-272
• 54 Lai E CS, Mok E PT, Tan E SY et al.. Endoscopic biliary drainage for severe acute cholangitis.  N Engl J Med. 1992;  326 1582-1586
• 55 Gores G J. A spotlight on cholangiocarcinoma.  Gastroenterology. 2003;  125 1536-1538 , (Review)
• 56 Born P, Rösch T, Willkomm G et al.. Initial experience with a new Yamakawa-type prosthesis for long-term percutaneous transhepatic drainage.  Endoscopy. 1999;  31 748-750
• 57 Peters R A, Williams S G, Lombard M, Karani J, Westaby D. The management of high-grade hilar strictures by endoscopic insertion of self-expanding metal endoprostheses.  Endoscopy. 1997;  29 10-16
• 58 Bown S G, Rogowska A Z, Whitelaw D E et al.. Photodynamic therapy for cancer of the pancreas.  Gut. 2002;  50 549-557
• 59 Schiefke I, Zabel-Langhennig A, Wiedmann M et al.. Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer.  Gastrointest Endosc. 2003;  58 213-219
• 60 Saltz L B, Cox J V, Blanke C et al.. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.  N Engl J Med. 2000;  343 905-914
• 61 Rothenberg M L, Oza A M, Bigelow R H et al.. Superiority of oxaliplatin and fluorouracil-leucovorin compared with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial.  J Clin Oncol. 2003;  21 2059-2063
• 62 Wiedmann M, Berr F, Schlefke J et al.. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study.  Gastrointest Endosc. 2004;  59 , (in press)
• 63 DeVreede I, Steers J L, Burch P A et al.. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.  Liver Transpl. 2000;  6 309-316
• 64 Sudan D, DeRoover A, Chinnakotia S et al.. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.  Am J Transplant. 2002;  2 774-779
• 65 Kaya M, de Groen P C, Angulo P et al.. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience.  Am J Gastroenterol. 2001;  96 1164-1169